Business Context and Reporting Period
This Form 6-K filing by Novo Nordisk A/S, dated July 29, 2024, reports on the company's ongoing share repurchase programme. Novo Nordisk is a leading global healthcare company headquartered in Denmark, employing approximately 66,000 people across 80 countries. The filing details transactions executed under a specific sub-programme initiated on May 6, 2024, which is part of a broader 12-month repurchase plan authorized to begin on February 6, 2024.
Key Financial Metrics
The filing focuses exclusively on capital allocation activities regarding share buybacks rather than operational financial performance.
- Total Repurchase Programme Cap: Up to DKK 20 billion over a 12-month period starting February 6, 2024.
- Current Sub-Programme Cap: Up to DKK 2.2 billion for the period May 7, 2024, to August 5, 2024.
- Cumulative Repurchases (Since Feb 6, 2024): 10,820,537 B shares.
- Cumulative Transaction Value: DKK 9,508,271,105.
- Average Purchase Price (Cumulative): DKK 878.72 per B share.
- Treasury Shares Held: 12,186,327 B shares (0.3% of total share capital).
The filing text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Recent Activity
Between July 22, 2024, and July 26, 2024, the company executed five transactions under the May 6, 2024 sub-programme:
| Date | Shares Purchased | Avg. Price (DKK) | Transaction Value (DKK) |
|---|---|---|---|
| July 22, 2024 | 39,000 | 909.36 | 35,465,111 |
| July 23, 2024 | 41,000 | 918.79 | 37,670,272 |
| July 24, 2024 | 41,000 | 909.74 | 37,299,164 |
| July 25, 2024 | 40,000 | 885.45 | 35,417,923 |
| July 26, 2024 | 40,500 | 879.94 | 35,637,745 |
As of July 26, 2024, the accumulated value under the specific May 6 programme reached DKK 1,980,536,332.
Guidance, Outlook, and Risks
Outlook: Novo Nordisk expects to continue repurchasing B shares up to the DKK 20 billion limit during the 12-month period beginning February 6, 2024. The company has utilized approximately 47.5% of the total authorized programme value as of late July 2024.
Risks and Contingencies: The filing does not disclose specific operational risks, contingencies, or unusual items. It notes that the repurchase programme is conducted in accordance with the EU Market Abuse Regulation (MAR) and Safe Harbour Rules.
Key Facts for Investor Verification
- Verify the remaining capacity of the DKK 20 billion share repurchase programme (approx. DKK 10.5 billion remaining as of July 26, 2024).
- Confirm the impact of the 0.3% treasury share holding on earnings per share (EPS) calculations in upcoming financial reports.
- Monitor the average purchase price trend, which has fluctuated between DKK 879.94 and DKK 918.79 in late July 2024.
- Check the company's official website (novonordisk.com) for daily transaction details as required by the filing.